National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Entrectinib (Rozlytrek®) for ROS1-positive advanced NSCLC. HTA ID: 21038

Entrectinib (Rozlytrek®) is indicated as monotherapy for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.

 

 

NCPE Assessment Process Complete
Rapid review commissioned 01/09/2021
Rapid review completed 28/09/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that entrectinib not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.